INVESTIGATION OF THE POTENTIAL IMPACT OF BENCHMARK DOSE AND PHARMACOKINETIC MODELING IN NONCANCER RISK ASSESSMENT

By Clewell Harvey J.   Gentry P. Robinan   Gearhart Jeffery M.  

Journal of Toxicology and Environmental Health, Vol. 52, Iss. 6, 1997-12 ,pp. : 475-515

Taylor & Francis Ltd

Access to resources Recommend Favorite

Quantitative low-dose assessment of seafood toxin, domoic acid, in the rat brain: application of physiologically-based pharmacokinetic (PBPK) modeling

By Kim C.S.   Ross I.A.   Sandberg J.A.   Preston E.  

Environmental Toxicology and Pharmacology, Vol. 6, Iss. 1, 1998-08 ,pp. : 49-58

Elsevier

Access to resources Recommend Favorite

Assessing the dose-dependency of allometric scaling performance using physiologically based pharmacokinetic modeling

By Kirman C.R.   Sweeney L.M.   Meek M.E.   Gargas M.L.  

Regulatory Toxicology and Pharmacology, Vol. 38, Iss. 3, 2003-12 ,pp. : 345-367

Elsevier

Access to resources Recommend Favorite

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK

By  

Cpt: Pharmacometrics & Systems Pharmacology, Vol. 4, Iss. 4, 2015-04 ,pp. : 226-230

John Wiley & Sons Inc

Access to resources Recommend Favorite

Physiologically Based Pharmacokinetic Modeling of Arsenic in the Mouse

By Gentry P. Robinan   Covington Tammie   Mann Sabine   Shipp Annette   Yager Janice   Clewell Harvey  

Journal of Toxicology and Environmental Health, Vol. 67, Iss. 1, 2004-06 ,pp. : 43-71

Taylor & Francis Ltd

Access to resources Recommend Favorite